Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

The Company announced a 10-year agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to manufacture and supply Regeneron's commercial bulk drug product at Fujifilm's North Carolina campus. The ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

Swiss drugmaker Roche will spend $50B to expand its U.S. manufacturing, while New York-based Regeneron will spend more than ...

“I think you might hear some noise at the high policy level, but I’m hopeful that at the actual day-to-day decision-making ...

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...